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Background: On the past decade a plethora of investigations were directed on identification of molecules involved
in breast tumorogenesis, which could represent a powerful tool for monitoring, diagnostics and treatment of this
disease. In current study we analyzed six previously identified medullary breast carcinoma autoantigens including
LGALS3BP, RAD50, FAM50A, RBPJ, PABPC4, LRRFIP1 with cancer restricted serological profile in different histological
types of breast cancer.
Methods: Semi-quantitative immunohistochemical analysis of 20 tissue samples including medullary breast
carcinoma, invasive ductal carcinoma, invasive lobular carcinoma and non-cancerous tissues obtained from patients
with fibrocystic disease (each of five) was performed using specifically generated polyclonal antibodies. Differences
in expression patterns were evaluated considering percent of positively stained cells, insensitivity of staining and
subcellular localization in cells of all tissue samples.
Results: All 6 antigens predominantly expressed in the most cells of all histological types of breast tumors and
non-cancerous tissues with slight differences in intensity of staining and subcellular localization. The most
significant differences in expression pattern were revealed for RAD50 and LGALS3BP in different histological types
of breast cancer and for PABPC4 and FAM50A antigens in immune cells infiltrating breast tumors.
Conclusions: This pilot study made possible to select 4 antigens LGALS3BP, RAD50, PABPC4, and FAM50A as
promising candidates for more comprehensive research as potential molecular markers for breast cancer
diagnostics and therapy.
Virtual slides: The virtual slides’ for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1860649350796892
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Breast cancer is the most common female cancer in the
world, with high mortality rate [1,2]. Identification of
biomarkers for early detection and new therapeutic tar-
gets of breast cancer helps to continuously reduce the
morbidity of this frequent pathology in women. This
entails resolving the physiological, cellular and molecular
processes underlying the complexity of breast tumor* Correspondence: kostjanez@ukr.net
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reproduction in any medium, provided the ordevelopment and associated tumor heterogeneity [3]. In
recent years efforts of many researchers are focused on
search of new markers and molecules involved in breast
tumorogenesis, which could be used in disease diagnos-
tics, treatment and prognosis.
Development and application of proteomic technolo-
gies based on detection of autoantibodies to tumor anti-
gens, including serological identification of antigens by
recombinant expression cloning (SEREX) [4-6], sero-
logical proteome analysis (SEPRA) [7-9], multiple affinity
protein profiling (MAPPing) [10] and high-density pro-
tein microarrays [11] have lead to identification of multi-
ply biomarkers of breast cancer inducing autoantibodyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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remains a major goal in both understanding the cellular
mechanisms associated with tumorogenesis and in
developing targets for the molecular therapy and diag-
nostics of cancer.
Protein tumor marker reflects consistent, biologically
relevant changes in the tumor. It has been described that
numerous autologous proteins of tumor cells, generally
known as tumor-associated antigens (TAAs), can elicit
humoral immune response in cancer patients as a result
of their aberrant expression [12], alternative splicing of
pre-messenger RNAs [13], point mutations [14], aber-
rant localization, folding [15], degradation [16] and/or
post-translation alteration [17,18]. Many breast cancer
antigens have been reported to be overexpressed at pro-
tein level in breast tumors; these include MUC1 [19],
HER2/neu [20], P53 [21], HSP-27 [22,23], GIPC-1 [24],
fibulin 1 [25] and cyclins B1 [26], D1 [27] and E [28].
Some tumor markers, for example, cyclin B1 also was
found to change its location in cancer cells and localized
predominantly in the cytosol [29], while normally it pre-
sents in the nucleus.
Our previous study was focused on identification of
novel TAAs of medullary breast carcinoma (MBC), a
relatively rare type of ductal carcinoma, which despite
anaplastic features has favorable prognosis for patients
[30-32]. High lyphocytic infiltration, indicating possible
presence of specific antigen within tumor lesion is a
distinctive feature of medullary breast carcinoma
[30,33,34]. Using SEREX approach and serological plaque-
spot assay we identified 41 potential antigens of medullary
breast carcinoma, and showed that 18 of them had cancer
restricted serological profile [35]. In this study protein
expression pattern of a small subset of 6 from 18
(lectin, galactoside-binding, soluble, 3 binding protein
(LGALS3BP); human RAD50 S. cerevisiae homolog
(RAD50); family with sequence similarity 50, member A
(FAM50A); poly(A) binding protein cytoplasmic 4
(PABPC4); recombination signal binding protein for im-
munoglobulin kappa J region (RBPJ) and leucine rich re-
peat (in FLII) interacting protein 1 (LRRFIP1)) antigens
was investigated by immunohistochemical analysis of differ-
ent histological types of breast cancer and non-cancerous
breast tissues from patients with fibrocystic disease. Semi-
quantitative analysis of positively stained cells, considering
intensity of staining, and subcellular localization in normal,
cancer and immune cells of lymphocytic infiltrate pre-
sented in some tumors using specifically generated poly-
clonal antibodies have been performed.
Methods
Clinicopathological data
Fresh breast cancer and non-cancerous breast tissue
(NCT) samples were obtained from 15 female patients(39–75 years) with primary breast carcinoma and 5
patients with fibrocystic disease (37–50 years) corres-
pondingly, who underwent surgery in the Dnipropet-
rovsk Clinical Oncological Center (Dnipropetrovsk,
Ukraine) between 2008 and 2010. Surgical specimens
were fixed with 10% buffered formalin, and paraffin em-
bedded sections were stained with hematoxilin and
eosin. All the tissue sample sections were reviewed to
confirm the original diagnosis by an expert pathologist.
The clinical and histopathological characteristics of these
patients are shown in Table 1. Breast cancer cases
included invasive ductal carcinoma (IDC) (n = 5), inva-
sive lobular carcinoma (ILC) (n = 5), and medullary car-
cinoma (n = 5). Clinicopathological data were obtained
from patient medical records and from the files kept at
the Department of Pathohistology of Dnipropetrovsk
Clinical Oncological Center. The study was approved by
the Ethics Committee of the Institute of Molecular Biol-
ogy and Genetics, NAS of Ukraine and informed con-
sent was obtained from all patients.
Cloning, expression and purification of recombinant
proteins
Specific cDNA of LGALS3BP, RAD50, FAM50A, RBPJ,
PABPC4 and LRRFIP1 genes, isolated from MBC cDNA
library Br502, was cloned into pGEX4T3 and/or pET28b
expression vectors, containing glutathione-S-transferase-
and 6His-tags respectively (Table 2). Expression of fused
recombinant proteins was induced by 1 mM IPTG at
37°C for 4 h in E.coli BL21 (DE3) pLysE cells trans-
formed by correspondent recombinant plasmids.
Proteins were affinity purified using GST-sepharose and
Ni-NTA-agarose according to manufacturers’ protocols.
Some expressed recombinant proteins were present in
the inclusion bodies of the pellet, which were washed
before the purification procedure according X.A. Yang
protocol [36]. Purity of proteins was analyzed by SDS-
PAGE. All proteins were dialyzed against phosphate buf-
fered saline (PBS), pH7.4, and then were used for
immunization of mice.
Generation of polyclonal antibodies
Polyclonal antibodies against LGALS3BP, RAD50,
FAM50A, RBPJ, PABPC4 and LRRFIP1 autoantigens
were generated according the protocol described below.
A primary dose of 20 mkg of each recombinant polypep-
tide was solubilized in Freund’s complete adjuvant
(Sigma, Aldrich, Germany) and administered intraperito-
neally in six- to 8-week-old female BALB/c mice four
times at 2-week intervals. Then, immunized mice (with
serum titer no less than 105–106) were boosted with
20 mkg of antigen in PBS by intraperitoneal injection.
After 3 days of the booster injection, blood was collected
from the mice, and the serum was separated.
Table 1 Characteristics of patients and their tissue samples
IDC (n = 5) ILC (n = 5) MBC (n = 5) NCT (n = 5)
Age (mean) 48.4 65.8 53 44.8
Age range 39-73 47-75 41-71 37-50
ER-positive 3 4 0 n/a
PR-positive 2 4 0 n/a
HER2-positive 3 2 0 n/a
Node positive 3 3 0 n/a
Ki-67 expression (range) 13-68% 8-29% n/a n/a
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by Western blotting of recombinant proteins and con-
firmed by immunohystochemical analysis of MBC tumor,
which was taken for generation of MBC cDNA library
Br502 [37] with depleted against corresponding recombin-
ant proteins polyclonal antibodies. Depletion of polyclonal
antibody was performed as follows: antibodies diluted
(1:10) in PBS were incubated overnight with correspondent
recombinant proteins (10 mkg) transferred on PVDF mem-
branes by standard blotting procedure. Decreasing of the
intensity of immunohistochemical staining of Br502 tumor
sections, when depleted antibody were used evidenced for
specificity of generated polyclonal antibodies compared
with undepleted ones.
Immunohistochemical analysis
Immunohistochemical analysis of breast cancer samples
with polyclonal Abs was performed according to stand-
ard protocol. Briefly, representative sections of breast
tumors were prepared from parafin blocks. Endogenous
peroxidase was quenched with H2O2 (3%) in 0.01% PBS.
After blocking of non-specific binding with avidin-biotin
blocking solution (Vector Laboratories, Burlingame, CA,
USA), tissue sections were incubated overnight at 4°C
with corresponded polyclonal antibodies (1:400). Then,
sections were incubated with biotinylated secondaryTable 2 Antigens used for generation of polyclonal antibodie
Antigen Full name NCB
refere
LGALS3BP Homo sapiens lectin, galactoside-binding, soluble, 3
binding protein
NM_005
RAD50 Homo sapiens RAD50 homolog (S. cerevisiae) NM_005
FAM50A Homo sapiens family with sequence similarity 50,
member A
NM_004
RBPJ Homo sapiens recombination signal binding protein
for immunoglobulin kappa J region
NM_203
PABCP4 Homo sapiens poly(A) binding protein, cytoplasmic 4
(inducible form)
NM_003
LRRFIP1 Homo sapiens leucine rich repeat (in FLII) interacting
protein 1
NM_004antibodies for 2 h at room temperature at 1:400
dilutions (goat anti-mouse biotinylated IgG, Sigma,
Steinheim, Germany), followed by incubation with
avidin-biotinperoxidase complex (Vector Laboratories,
Burlingame, CA, USA) for 30 min at RT and developed
with diaminobenzidine solution. Serum from non-
immune mouse was used as negative control. Immuno-
histochemical staining of all breast cancer and
non-cancerous tissue slides was performed during one
experiment in equal conditions for each of antigens ana-
lyzed. Haematoxylin was used for counterstaining.
Standard microscopy was performed using a Zeiss Uni-
versal microscope (Zeiss, Germany), and images were
captured using digital Axiocam software.
Taking into account the fact that the expression of the
studied antigens in normal and tumor breast tissues are
poorly studied, we evaluated the staining intensity for
each antigen comparing the slides of non-cancerous and
cancerous breast tissue samples of different histological
types, which were processed with correspondent poly-
clonal antibody under the same conditions. Tissue slides
were analyzed using a four point semi-quantitative scale
for nuclear and cytoplasmic optical staining intensity
(graded as 3+ (strong), 2+ (moderate), 1+ (weak), 0 (no
staining)) and for the percentage of positively stained
cells (0 – no staining, 1 – <10% of the cells, 2 – 11 – 50%s
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biologically representative areas, which contained a
mean number of 150 cells (min 72 – max 180), percent-
age of positive cells was assessed as percent of cells exhi-
biting reactivity as average in 10 fields at high
magnification (x400). The area of interest was selected
randomly, excluding stromal cells and artifacts. Staining
intensity and percent reactivity were recorded as mean
observed in ten high power fields. The same slides were
viewed again by each one of 3 month later, independ-
ently of the first vision.
Results
In our previous studies, focused on identification of
novel TAAs of medullary breast carcinoma, we found 41
antigens [37], 18 of which had cancer-restricted sero-
logical profile as was shown by phage based allogenic
serological screening [35]. TAAs identified represent a
diverse range of cellular proteins, some of which were
shown to be implicated in cancer development, particu-
larly lectin, galactoside-binding, soluble, 3 binding pro-
tein (LGALS3BP) [38], double-strand break repair factor
RAD50 [39], nuclear protein with unknown function
FAM50A [40], poly(A) binding protein cytoplasmic 4
(PABPC4) [41], mediator of Notch signaling RBPJ [42]Figure 1 Immunohystochemical staining reaction of LGALS3BP, RAD5
non-cancerous tissues. Cancer cells of MBC and IDC demonstrated mode
in ILC samples weak cytoplasmic and moderate nuclear staining was obser
part of normal epithelial cells was detected. Predominantly strong (3+) nuc
was detected. Antigen FAM50A had moderate nuclear and weak cytoplasm
L – lymphocytic infiltrate. Magnification 400x.and transcription factor LRRFIP1 [43]. To characterize
their expression profile and subcellular localization in
cancer cells of human breast carcinomas and cells of
non-cancerous breast tissues immunohistochemical ana-
lysis using specific polyclonal antibodies has been per-
formed. For generation of polyclonal antibodies cDNAs
of LGALS3BP, RAD50, FAM50A, RBPJ, PABPC4 and
LRRFIP1 antigens from MBC λ phage cDNA library
were cloned in pGEX4T3 and pET28b plasmid vectors
in the frame with GST- and His-tags correspondently
for further affine purification (Table 2). All recombinant
plasmids were expressed in bacteria and their affinity
purified recombinant products were used for
immunization of mice (Table 2). Specificity of generated
antibodies was tested as described in Materials and
Methods (data not shown).
Positive staining for LGALS3BP antigen was observed
in more than 50% of all cells in tissue sections of the
most breast tumors types and non-cancerous breast tis-
sues (Figure 1), (Table 3). Tumor cells of IDCs and
MBCs showed weak nuclear (1+) and moderate (2+) to
strong (3+) cytoplasmic staining, while all ILCs showed
opposite expression pattern with weak (1+) cytoplasmic
and moderate (2+) nuclear staining (Table 4). Notably,
strong LGALS3BP staining was observed at the apical0, and FAM50A MBC-associated antigens in breast cancer and
rate to strong cytoplasmic and weak nuclear LGALS3BP staining, while
ved. Strong positive LGALS3BP staining of cytoplasm and the apical
lear RAD50 staining in normal and cancer cells of MBC, IDC, and ILC
ic staining in NCT and tumor samples. C – cancer cells,




Normal cells Cancer cells Immune cells
0 1 2 3 0 1 2 3 0 1 2 3
LGALS3BP MBC n/a n/a n/a n/a - - 1/5 4/5 - - 1/5 4/5
IDC n/a n/a n/a n/a - - 1/5* 4/5 - - 1/1* -
ILC n/a n/a n/a n/a - - - 5/5 - - - -
NCT - - - 5/5 - - - - - - - -
RAD50 MBC n/a n/a n/a n/a - - - 5/5 - - - 5/5
IDC n/a n/a n/a n/a - - 1/5* 4/5 - - - 1/1*
ILC n/a n/a n/a n/a - - - 5/5 - - - -
NCT - - - 5/5 - - - - - - - -
FAM50A MBC n/a n/a n/a n/a - - - 5/5 - - 1/5 4/5
IDC n/a n/a n/a n/a - - 1/5* 4/5 - - - 1/1*
ILC n/a n/a n/a n/a - - 2/5 3/5 - - - -
NCT - - - 5/5 - - - - - - - -
RBPJ MBC n/a n/a n/a n/a - - - 5/5 - - - 5/5
IDC n/a n/a n/a n/a - - 1/5* 4/5 - - - 1/1*
ILC n/a n/a n/a n/a - - - 5/5 - - - -
NCT - - - 5/5 - - - - - - - -
PABPC4 MBC n/a n/a n/a n/a - - - 5/5 - - 1/5 4/57**
IDC n/a n/a n/a n/a - - 1/5* 4/5 - - - 1/1*
ILC n/a n/a n/a n/a - - - 5/5 - - - -
NCT - - - 5/5 - - - - - - - -
LRRFIP1 MBC n/a n/a n/a n/a - - - 5/5 - - - 5/5
IDC n/a n/a n/a n/a - - 1/5* 4/5 - - 1/1* -
ILC n/a n/a n/a n/a - - - 5/5 - - - -
NCT - - - 5/5 - - - - - - - -
MBC – medullary breast carcinoma, IDC-invasive ductal carcinoma, ILC – invasive lobular carcinoma, NCT – non-cancerous tissue; n/a - normal cells were not
available within tumor sample; 0 - no staining, 1 - <10% of the positively stained cells, 2 - 10-50% of the positively stained cells, 3 > 50% of the positively stained
cells; * - one case of IDC which was heavily infiltrated by lymphocytes; ** - PABPC4 positive staining was observed in 50-70% of immune cells.
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non-cancerous tissues (Figure 1) and in some ILCs
cases.
All 15 breast cancer and 5 non-cancerous tissue
samples were positive for the DNA reparation factor
RAD50 (Figure 1), (Table 3). We observed moderate
(2+) to strong (3+) nuclear RAD50 staining with no
cytoplasmic staining apparent in normal and cancer cells
in the most cases. However, in 4 of 5 ILCs cases decreas-
ing of the intensity of nuclear staining (moderate (2+))
was detected.
Analysis of FAM50A protein expression revealed that
more than 50% of cells were positively stained in cancer
and non-cancerous tissue sets (Figure 1), (Table 3).
FAM50A protein predominantly was distributed in nu-
cleus and cytoplasm of cancer cells of all tumor samples
with preferentially moderate (2+) and weak (1+) positive
staining respectively (Table 4).RBPJ staining was indicated in the most of cancer and
normal cells (Figure 2), (Table 3). Moderate (2+) to
strong (3+) nuclear and weak (1+) cytoplasmic staining
(Table 4) was detected in MBC and IDC tissue samples.
In ILC and NCT tissues samples predominantly moder-
ate (2+) nuclear and additional weak (1+) cytoplasmic
staining in some cases was detected.
Moderate (2+) to strong (3+) PABPC4 positive staining
was exclusively observed in cytoplasm of normal and
cancer cells of non-cancerous and cancer tissue samples
with no relation to histological type (Figure 2), (Tables 3
and 4).
LRRFIP1 nuclear and cytoplasmic expression was indi-
cated in more than 50% of all tissue samples (Figure 2),
(Table 3). This protein was located in nucleus and cyto-
plasm of both cancerous and non-cancerous tissue sets
with moderate (2+) to strong (3+) nuclear and weak (1+)
cytoplasmic staining, however in MBC tissues moderate
Table 4 Descriptive data of 6 antigens intracellular distribution and insensitivity of staining in tissue samples*
Antigens
Case Tissue sample Age LGALS3BP RAD50 FAM50A RBPJ PABPC4 LRRFIP1
1 MBC 42 N1+, C2+ N3+ N1+, C1+ N2+, C1+ C3+ N2+, C2+
2 MBC 40 N1+, C3+ N2+ N2+, C2+ N2+, C1+ C3+ N2+, C2+
3 MBC 46 N1+, C3+ N3+ N1+, C1+ N2+, C1+ C2+ N3+, C2+
4 MBC 70 N2+, C2+ N3+, C1+ N2+, C1+ N3+, C1+ C3+ N3+, C1+
5 MBC 57 N1+, C3+ N3+ N2+, C1+ N3+, C1+ C3+ N2+, C2+
6 IDC 66 N1+, C3+ N3+ N2+, C1+ N2+, C1+ C3+ N3+, С1+
7 IDC 38 N1+, C2+ N2+ N2+, C2+ N2+, C1+ C2+ N3+, С1+
8 IDC 68 N1+, C2+ N3+ N2+, C1+ N3+, C2+ C3+ N2+, С1+
9 IDC 72 N1+, C2+ N3+ N2+, C1+ N2+, C1+ C3+ N3+, С1+
10 IDC 63 N1+, C3+ N3+ N2+, C1+ N3+, C1+ C2+ N2+, С1+
11 ILC 66 N2+, C1+ N2+ N2+, C1+ N2+, C1+ C3+ N2+
12 ILC 38 N2+, C1+ N3+ N2+, C1+ N2+ C2+ N3+, C1+
13 ILC 68 N2+, C1+ N2+ N2+, C1+ N2+ C3+ N3+, C1+
14 ILC 72 N2+, C1+ N2+ N2+, C1+ N2+, C1+ C2+ N2+
15 ILC 63 N2+, C1+ N2+ N2+, C1+ N2+ C3+ N3+, C1+
16 NCT 43 N2+, С1+ N3+ N2+, C1+ N1+, C1+ C3+ N2+, C1+
17 NCT 50 N1+, C2+ N3+, C1+ N3+, C1+ N2+, C1+ C3+ N3+
18 NCT 46 N1+, C2+ N3+ N2+, C1+ N1+, C1+ C3+ N2+, C1+
19 NCT 48 N2+, С1+ N3+ N2+, C1+ N2+ C2+ N3+, C1+
20 NCT 37 N1+, C1+ N3+ N2+, C1+ N2+ C2+ N3+
MBC – medullary breast carcinoma, IDC – invasive ductal carcinoma, ILC – invasive lobular carcinoma, NCT – non-cancerous tissue. N – nuclear staining,
C – cytoplasmic staining; * staining intensity was graded as 3+ (strong), 2+ (moderate), 1+ (weak).
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(Figure 2). According to the literature data some of the
analyzed proteins could be involved in modulation of
immune response [41,42,44-46]. Taking this fact into ac-
count we performed immunohistochemical analysis of
tumor regions of all MBC and 1 case of IDC highly infil-
trated by lypmphocytes, with correspondent polyclonal
antibodies. We have shown that all proteins expressed in
the most of immune cells of lymphocytic infiltrate (up to
90%) (Table 3), with exception for PABPC4 which posi-
tive staining was observed only in 50–70% of immune
cells (Figure 3). Moreover, PABPC4 showed more inten-
sive cytoplasmic staining of immune cells compared with
cancer and normal cells (Figure 3), as well as nuclear
antigen with unknown function FAM50A. More inten-
sive compared with cancer and normal cells FAM50A
positive staining was detected in the nucleus of immune
cells (Figure 3).
Discussion
The identification of breast cancer markers has been the
focus of extensive research in past decades, there still an
urgent need for good cancer biomarkers remains. More-
over, characterization of these proteins and identification
of the alterations that distinguish cancer cells fromnormal ones will help to understand the molecular
mechanisms of cancerogenesis. In previous study we
identified by SEREX-approach 41 novel medullary breast
carcinoma autoantigens, 18 of which had cancer-related
serological profile [35]. During this study expression pat-
tern of 6 from 18 potential MBC-derived antigens were
studied by immunohistochemistry in tissue samples
obtained from patients with different histological types
of breast cancer and fibrocystic disease using specifically
generated polyclonal antibodies. Medullary breast car-
cinoma, lobular and ductal invasive breast carcinomas’
tissue samples were taken for immunohistochemical in-
vestigation of expression patterns of above mentioned
proteins. It’s known that lobular and ductal carcinomas
derive both from the breast terminal duct lobular units
[47] and the terminology “ductal” and “lobular” is still
being used for historical reasons and to date there is no
evidence to suggest that these tumors arise from ductal
or lobular epithelial cells. Thus, the differences in their
morphology are likely to reflect the different mechan-
isms of carcinogenesis rather than the anatomical origin
of the lesions [48]. For example, it was demonstrated
that 5.8% of the transcriptionally regulated genes were
differentially expressed in ILCs compared to grade- and
molecular subtype-matched IDCs [49]. Identification
Figure 2 Immunohystochemical staining reaction of RBPJ, PABPC4, and LRRFIP1 MBC-associated antigens in breast cancer and
non-cancerous tissues. Antigen RBPJ had moderate nuclear and weak cytoplasmic staining of normal and cancer cells of NCT, MBC, and IDC,
except for ILC samples which showed only moderate (2+) nuclear staining. Moderate to strong positive PABPC4 staining was detected in
cytoplasm of normal and cancer cells of non-cancerous and cancer tissue samples. Cancer cells of IDC and ILC, and normal cells of
non-cancerous tissues had moderate to strong nuclear and weak cytoplasmic LRRFIP1 staining, but in MBC moderate cytoplasmic LRRFIP1
staining was observed. C – cancer cells, L – lymphocytic infiltrate. Magnification 400x.
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each type of breast cancer will help to design more pre-
cise therapeutic and diagnostic approaches for curing of
this type of malignancy.
During this preliminary study, we investigated expres-
sion pattern of 6 MBC autoantigens, including secretory
protein LGALS3BP, 2 nuclear proteins (RAD50,
FAM50A), one cytoplasmic protein (PABPC4) and 2
tratscription factors (RBPJ, LRRFIP1), in different histo-
logical types of breast cancer and non-cancerous tissueFigure 3 Immunohistochemical staining of PABPC4 (A) and FAM50A (
carcinoma. Both antigens showed more intensive staining of immune cell
was detected only in a part of immune cells. FAM50A showed preferentiall
by arrows. C – cancer cells, L – lymphocytic infiltrate. Magnification 400x.samples by immunohistochemical analysis. Despite the
fact that automated measurement using digital slide
scanners and computer-aid methods are increasingly
used for immunohystochemical analysis, during this
study we used visual semi-quantitative evaluation of
MBC antigens expression pattern by expert pathologist
because high correlation between these two approaches
was recently shown [50-52].
It was shown that all analyzed proteins expressed in
the most cells of non-cancerous and cancer tissueB) antigens in cells of lymphocytic infiltrate of medullary breast
s compared with cancer cells. Positive cytoplasmic PABPC4 staining
y nuclear staining in immune cells. Positively stained cells are indicated
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revealed for some antigens in breast carcinomas of dif-
ferent histological types.
LGALS3BP (also known as MAC-2BP and 90K pro-
tein) was originally identified as a tumor-associated anti-
gen in the culture supernatant of human breast cancer
cells [53]. Early works focused on study of LGALS3BP
showed its expression in more than 80% of breast can-
cer tissues, but not in non-cancerous normal mam-
mary gland surrounding the cancer cells [53].
Immunohistochemical analysis of LGALS3BP expres-
sion in several tumors, including breast carcinomas,
revealed LGALS3BP positive staining predominantly in
cytoplasm [54]. During our study, we also, observed
moderate to strong LGALS3BP positive staining in cyto-
plasm and weak nuclear staining of IDC and MBC cells.
Interestingly, that in ILC tumors we detected opposite
pattern of LGALS3BP expression with moderate nuclear
and weak cytoplasmic staining. Moreover, during this
study we observed an explicit apical membrane staining
of LGALS3BP in some of epithelial cells in breast tissues
of patients with fibrocystic disease and epithelial cells lin-
ing the normal ducts in ILCs, contrary to mentioned
above literature data [53]. This strong apical membrane
staining of LGALS3BP may partly be explained by its
ability to be secreted by different types of cells including
epithelial cells [55-57].
RAD50 is a highly conserved DNA double-strand
break repair factor [39]. Its aberrantly reduced protein
expression was reported in 3% of breast tumors (pre-
dominantly ER/PR/ERBB2 triple-negative and higher-
grade familial breast tumors) [57]. In our investigation
we also showed strong RAD50 nuclear staining of non-
cancerous and cancer cells. However, in 4 from 5 ILC
cases we observed rather moderate than strong RAD50
positive staining in the nucleus of cancer cells. Since,
down-regulation of some genes including RAD50 was
shown in ILCs [49]; our results partially confirmed the
data about reduced RAD50 expression in ILC tumors.
However, this fact should to be further investigated on a
large number of samples.
FAM50A (also known as XAP5) is a poorly studied
protein with unknown function having signal for nuclear
localization [40]. Here, we describe for the first time its
subcellular localization and expression pattern in cancer
and non-cancerous breast tissues. According to our find-
ings FAM50A protein is expressed both in nucleus and
cytoplasm in the most cells of cancer and non-cancerous
breast tissues without any significant differences. How-
ever we found stronger FAM50A nuclear staining in
immunocytes compared with cancer and non-cancerous
breast cells.
PABPC4 (or inducible PABP (iPABP)) a homolog of
PABP, have critical roles in RNA processing beyondsimply binding to poly(A) sequences [41]. According to
the literature data PABPC4 is a diffusely cytoplasmic
protein that can be localized to stress granules [58]; its
expression is induced upon stimulation of peripheral T
cells [41]. The fact that induction of PABPC4 coincides
with the induction of lymphokine mRNA in activated T
cells suggests that perhaps iPABP is necessary for regula-
tion of stability of labile mRNA species [41]. In our
study, we observed moderate to strong PABPC4 positive
staining in cytoplasm in the most of cancer and normal
cells of all tissue samples and in part of immunocytes.
One may be speculated that PABPC4 expression can be
restricted to activated T cells at least in MBC tumors,
and possibly contributes to a more effective immune re-
sponse that can be associated with good prognosis for
patients with this tumor type. However, to confirm this
assumption additional study has to be performed.
RBPJ is a primary transcription mediator of canonical
Notch signaling [59], which participates in cell fate de-
termination, and is involved in the regulation of tumor
behavior in multiple decisions [60]. It has been shown
previously, that RBPJ protein can be detected in the nu-
cleus as well as in the cytoplasm and it subcellular distri-
bution changes in defined physiological contexts [61-64].
In all cancer and non-cancerous cases predominantly
moderate nuclear RBPJ and weak cytoplasmic staining
was detected, however in some MBC and IDC cases
strong nuclear staining was revealed. These differences
may be associated with histological and molecular fea-
tures of these tumor types.
LRRFIP1 is ubiquitously expressed and found in the
nuclear and cytoplasmic compartments [65]. This pro-
tein acts as transcriptional repressor of some genes
[45,46,66] and indirectly throught interaction with
Flightless 1 protein involved in actin severing, capping
and cytoskeletal rearrangement [67]. Notably, LRRFIP1
can be mutated in breast tumors and soft tissue sarco-
mas [68], and may be involved in the regulation of cell
growth [43]. We observed strong nuclear and weak cyto-
plasmic distribution of LRRFIP1 in cancer and normal
cells except for MBC tumors, which showed moderate
cytoplasmic staining in addition to strong nuclear
staining.
Thus, during this study we described for the first time
expression patterns of 6 potential MBC-associated anti-
gens, including LGALS3BP, RAD50, FAM50A, RBPJ,
PABPC4, LRRFIP1 in different histological types of
breast carcinomas and non-cancerous breast tissues by
immunohistochemical analysis. Our data indicate that all
6 antigens predominantly expressed in the most cells of
all histological types of breast tumors, non-cancerous
tissues, and immunocytes with slight differences in in-
tensity of staining and subcellular localization. The most
significant differences were observed for RAD50 and
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breast carcinomas. During this study we described for
the first time expression pattern of poorly studied anti-
gen FAM50A and observed its more intensive nuclear
staining in the immune cells compared with cancer and
non-cancerous cells. Additionally increased expression
of other antigen PABPC4 was observed in restricted
number of immune cells infiltrating breast tumors.
These observations possibly reflect molecular changes
that occur during breast carcinogenesis in different
histological types of breast cancer and indicate that
RAD50 and LGALS3BP antigens are promising candi-
dates for more comprehensive research as potential mo-
lecular markers for breast cancer diagnostics and
therapy. Moreover, antigens FAM50A and PABPC4 are
intriguing targets for investigation of the features of the
immune response in patients with highly infiltrating
breast tumors including MBC, which despite anaplastic
features has favorable prognosis.
Conclusions
In this study we determined for the first time expression
patterns of 6 potential MBC-associated antigens, includ-
ing LGALS3BP, RAD50, FAM50A, RBPJ, PABPC4, and
LRRFIP1, in non-cancerous cells of the breast, cancer
and immune cells of different histological types of breast
carcinomas by immunohistochemical analysis. The most
significant differences in expression pattern were
revealed for RAD50 and LGALS3BP in cancer cells of
different histological types of breast cancer and for
PABPC4 and FAM50A antigens in immune cells infil-
trating breast tumors. This work is a pilot study, which
made possible to select 4 potential breast cancer markers
(FAM50, PABC4, RAD50, LGALS3BP) for further stud-
ies with larger cohorts of patients with different histo-
logical types of breast cancer using automated
measurement systems for immunohistochemical ana-
lysis. Data obtained can contribute to investigations in
the field of breast cancer genesis, diagnostics and ther-
apy, and may be of interest for a wide range of research-
ers including those who already focused on precise study
of indicated proteins.
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